6% and 2.4%) and treatment discontinuations
due to AEs (1.7% and 0.7%) were comparable among patients with and without DEP/BPD history. Conclusions: In this pooled analysis of phase 3 trial results, high SVR rates and low rates of treatment discontinuation were achieved with the 3D regimen in patients with a history of DEP/BPD. Most AEs were mild. These data support a role for the 3D±RBV regimen among patients who were previously not considered candidates for IFN treatment. Disclosures: David R. Nelson – Advisory Committees or Review Panels: Merck; Grant/Research Support: Abbot, BMS, Beohringer Ingelheim, Gilead, Genentech, Merck, Bayer, Idenix, Vertex, Jansen K. Rajender Reddy – Advisory Committees or Review Panels: Genentech-Roche, Merck, Janssen, Vertex, Gilead, BMS, Novartis, Abbvie; Grant/Research Support: Merck, BMS, Ikaria, Gilead, Janssen, AbbVie Adrian M. Di Bisceglie – Grant/Research Support: Genentech, Selleck Trametinib Gilead, AbbVie, BMS Peter Ferenci – Advisory Committees or Review Panels: Roche, Idenix, MSD, Jans-sen, AbbVie, BMS, Tibotec, Wnt drug BVdhringer Ingelheim; Patent Held/Filed: Madaus Rottapharm; Speaking and Teaching: Roche, Gilead, Roche, Gilead, Salix Darrell H. Crawford – Advisory Committees or Review Panels: Roche
Products Pty Ltd, Bristol Myers Squibb, Gilead Sciences, Novartis, MSD, Abbvie, Jansen; Consulting: Roche Products Pty Ltd; Grant/Research Support: Roche Products Pty Ltd; Speaking and Teaching: Roche Products Pty Ltd, Bristol Myers Squibb, Gilead Sciences, MSD Rudolf E. Stauber – Advisory Committees or Review Panels: Gilead, Janssen-Cilag, AbbVie, BMS; Grant/Research Support: MSD; Speaking and Teaching: Roche Victor de Ledinghen – Advisory Committees or Review Panels: Merck, Janssen, Gilead, BMS, Abbvie; Grant/Research Support: Gilead, Janssen; Speaking and Teaching: AbbVie, BMS Holger Hinrichsen – Advisory Committees or MCE Review Panels: Janssen, Gilead, Abbvie; Speaking and Teaching: Roche, MSD David Eric Bernstein – Consulting: Merck; Grant/Research Support: GIlead, Phar-masset, Vertex, BMS; Speaking and Teaching: Gilead Robert J.
de Knegt – Advisory Committees or Review Panels: MSD, Roche, Norgine, Janssen Cilag; Grant/Research Support: Gilead, MSD, Roche, Janssen Cilag, BMS; Speaking and Teaching: Gilead, MSD, Roche, Janssen Cilag Tarek Hassanein – Advisory Committees or Review Panels: AbbVie, Bristol-Myers Squibb; Grant/Research Support: AbbVie Pharmaceuticals, Boehringer-Ingleheim, Bristol-Myers Squibb, Eiasi Pharmaceuticals, Gilead Sciences, Janssen R&D, Idenix Pharmaceuticals, Ikaria Therapeutics, Merck Sharp & Dohme, Roche Pharmaceuticals, Ocera Therapeutics, Salix Pharmaceuticals, Sundise, TaiGen Biotechnology, Takeda Pharmaceuticals, Vital Therapies; Speaking and Teaching: Baxter, Bristol-Myers Squibb, Gilead, Salix Suzanne Norris – Advisory Committees or Review Panels: AbbVie Junyuan J. Xiong – Employment: AbbVie Barbara H.